As of June 21, 2025, Forward Pharma A/S (FWP) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Forward Pharma A/S's Forward P/E to Peers
To better understand Forward Pharma A/S's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Forward Pharma A/S (FWP) | - |
| Zealand Pharma A/S (ZEAL.CO) | 67.24 |
| Orphazyme A/S (ORPHA.CO) | 16.18 |
| Genmab A/S (GMAB.CO) | 13.95 |
| Bavarian Nordic A/S (BAVA.CO) | 10.56 |
| Ocuphire Pharma Inc (OCUP) | 9.27 |
Compared to its competitors, Forward Pharma A/S's Forward P/E is difficult to compare due to insufficient data.